Study design of the phase II PHOEBUS trial of MaaT013

MaaT033 is a fecal microbiota product produced from pooled allogeneic human material. The GvHD Hub has previously reported on MaaT013 for gastrointestinal and steroid-refractory graft-versus-host disease. Previous studies have suggested that use of fecal microbiota therapy could improve outcomes, such as overall survival after an allogeneic hematopoietic stem cell transplant.¹

At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Florent Malard presented the planned study design and methods of the phase II PHOEBUS trial (NCT05762211) of MaaT013 in patients ≥50 years with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplant.

Inclusion criteria¹

Figure 1 outlines the key inclusion criteria of the PHOEBUS trial.

Figure 1. Key inclusion criteria

Study design¹

• The primary objective is overall survival at 12 months
• Secondary objectives include quality of life, safety, and incidence of graft-versus-host disease
• Patients will receive three MaaT013 or placebo capsules per day for 7 days before initiation of the conditioning regimen (between Day −21 and Day −7)
• Patients will have monthly follow-ups until Month 6, and then every 3 months until Month 12

Key facts¹

Figure 2. Key facts about the PHOEBUS trial* 

*Data from Malard.¹ Created with BioRender.com

This trial is still ongoing and the first results are expected later in 2024.